Shares of Elanco Animal Health (ELAN) have declined 6.1% since Jul 9, following the completion of the divestiture of its aqua business to Merck Animal Health, a subsidiary of Merck & Co.  (MRK) , for approximately $1.3 billion in cash. Although its shares are down, Elanco is focused on the long-term positive strategic move that will enable the company to concentrate on high-value opportunities in pet health and livestock sustainability while enhancing its financial flexibility.The company plans to use the n ...